Next Gen Diagnostics Announces Opening of a US Sequencing and Bioinformatics Laboratory in Cambridge, Massachusetts

WEST PALM BEACH, FL / ACCESSWIRE / June 11, 2024 / Next Gen Diagnostics has announced the opening of its first US laboratory in Cambridge, Massachusetts. This facility aims to provide low-cost, fully integrated bacterial sequencing and bioinformatics services to US customers. The lab will utilize the NGD100 high throughput microfluidic sequencing sample preparation instrument and automated pathogen bioinformatics systems.

"NGD has assembled the technologies and capabilities to leverage the vanishing costs of sequencing," said Dr. Paul A. Rhodes, NGD's founder and CEO. This initiative will benefit researchers and infection control teams by offering whole genome sequencing (WGS) results with high throughput, low cost, and quick turnaround, unlocking transformative potential.

The NGD100 instrument processes 48 bacterial WGS libraries in parallel with minimal human intervention and lower reagent use. This capability is complemented by NGD's automated bioinformatics, which performs quality control and relatedness determination. These features are delivered through a powerful user interface enabling effective infection control and antibiotic resistance analysis.

NGD will demonstrate the NGD100 system and bioinformatic user interface at ASM Microbe 2024 in Atlanta from June 14-16.